COMMUNIQUÉS West-GlobeNewswire

Virbac : Déclaration d'actions et de droits de vote 02/2026
10/03/2026
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights 02/2026
10/03/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Transactions in connection with share buy-back program
10/03/2026
Company announcement no. 4 - 26 10 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs
10/03/2026
MAPS delegation includes senior researchers, policy experts, and Veterans from the US, Europe, Australia, and the Middle East. The CND is a central drug policy-making body in the UN, playing the leading role in [...]
HOOPP delivers strong 2025 results for Ontario’s healthcare community
10/03/2026
Net assets reach $132 billion, with nearly half invested in Canada, and membership now exceeding 500,000 TORONTO, March 10, 2026 (GLOBE NEWSWIRE) -- The Healthcare of Ontario Pension Plan’s net assets grew to $132 [...]
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
10/03/2026
RUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.(“Glucotrack”, or the “Company”) (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel [...]
API Innovation Center Highlights Fragility in U.S. Drug Supply Chain in New White Paper
10/03/2026
Report outlines how measuring supply chain fragility can guide policy, investment and procurement reform ST. LOUIS, March 10, 2026 (GLOBE NEWSWIRE) -- The API Innovation Center (APIIC), a nonprofit dedicated to [...]
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
10/03/2026
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Natural Remedies Advances Sleep Health Research with Holixer During National Sleep Awareness Month
10/03/2026
BANGALORE, India, March 10, 2026 (GLOBE NEWSWIRE) -- During National Sleep Awareness Month in March, Natural Remedies is highlighting human clinical research on Holixer , a standardized holy basil extract, that applies [...]
SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a [...]
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
10/03/2026
Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity Organizational [...]
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
10/03/2026
Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release HINGHAM, Mass., March 10, 2026 (GLOBE [...]
UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives
10/03/2026
Clover Health's early adoption of real-time patient access to claims data on Kno2 is made possible by underlying infrastructure powered by Counterpart Health NOTICE: This is an updated version of a press release [...]
Spectral AI Schedules 2025 Fourth Quarter and Full Year Financial Results and Conference Call
10/03/2026
DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
10/03/2026
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurological condition [...]
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
10/03/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 [...]
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
10/03/2026
A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company [...]
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
10/03/2026
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed [...]
Longeveron Announces Private Placement of up to $30 Million
10/03/2026
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules [...]

Pages